suramin has been researched along with Cancer of Kidney in 13 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin was found to affect the Wilms' tumor (WT) cell line, W13, by inhibiting in vitro growth (half-maximal inhibitory dose (ID50)=11 microM), insulin like growth factor II (IGF-II) cell binding (ID50 = 10 microM) and IGF-II induced DNA synthesis (ID50 = 8 microM)." | 5.29 | Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. ( Garvin, AJ; Hazen-Martin, DJ; Vincent, TS, 1996) |
| " The suramin dosing nomogram used in phase I and II portions of the trial yielded the desired plasma level of 10-50 micromol/L from 4." | 2.73 | Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. ( Au, JJ; Bukowski, RM; Cooney, MM; Dreicer, R; Elson, P; Ganapathi, R; George, S; Mekhail, T; Rini, BI; Roman, S; Shen, T; Wientjes, GM, 2008) |
| "Suramin was administered by intravenous infusions over 1 hour." | 2.69 | Phase II trial of suramin in patients with metastatic renal cell carcinoma. ( Dreicer, R; See, WA; Smith, DC; Williams, RD, 1999) |
| " Pharmacokinetic parameters were determined by the ADAPT II MAP-Bayesian parameter estimation program." | 2.67 | Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. ( Albino, AP; Bajorin, DF; Iversen, J; Louison, C; Motzer, RJ; Nanus, DM; O'Moore, P; Reuter, V; Scher, HI; Tong, WP, 1992) |
| "Suramin was found to affect the Wilms' tumor (WT) cell line, W13, by inhibiting in vitro growth (half-maximal inhibitory dose (ID50)=11 microM), insulin like growth factor II (IGF-II) cell binding (ID50 = 10 microM) and IGF-II induced DNA synthesis (ID50 = 8 microM)." | 1.29 | Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. ( Garvin, AJ; Hazen-Martin, DJ; Vincent, TS, 1996) |
| "Suramin is a polyanionic compound used clinically for the treatment of trypanosomiasis, which is known to inhibit the action of many protein factors in vitro." | 1.28 | Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. ( Gomella, LG; Kasid, A; LaRocca, RV; Linehan, WM; Myers, CE; Sargent, ER; Stein, CA; Wade, TP, 1992) |
| "Suramin is a synthetic polyanionic compound which is capable of altering the function of a number of biologic systems and inhibiting the activity of a variety of protein and growth factors." | 1.28 | Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. ( Chang, SY; Kozlowski, JM; Lee, C; Sherwood, ER; Yu, DS, 1992) |
| "Suramin sodium is an aromatic polysulfonated compound that was originally introduced as an antiparasitic agent in the 1920s." | 1.28 | A pilot study of suramin in the treatment of metastatic renal cell carcinoma. ( Cooper, MR; Danesi, R; La Rocca, RV; Myers, CE; Stein, CA; Uhrich, M, 1991) |
| "In cells derived from two human renal carcinomas only the precursor form of epidermal growth factor (EGF) was found." | 1.27 | Analysis of epidermal growth factor and epidermal growth factor receptor expression in human renal carcinoma cell cultures. ( Cerná, H; Damková, M; Hlozánek, I; Jakoubková, J; Sloncová, E; Sovová, V; Vydra, J, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 9 (69.23) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| George, S | 1 |
| Dreicer, R | 2 |
| Au, JJ | 1 |
| Shen, T | 1 |
| Rini, BI | 1 |
| Roman, S | 1 |
| Cooney, MM | 1 |
| Mekhail, T | 1 |
| Elson, P | 1 |
| Wientjes, GM | 1 |
| Ganapathi, R | 1 |
| Bukowski, RM | 1 |
| Marutsuka, K | 1 |
| Hasui, Y | 1 |
| Asada, Y | 1 |
| Naito, S | 1 |
| Osada, Y | 1 |
| Sumiyoshi, A | 1 |
| Bassukas, ID | 1 |
| Myers, RB | 1 |
| Parker, M | 1 |
| Grizzle, WE | 1 |
| Vincent, TS | 1 |
| Hazen-Martin, DJ | 1 |
| Garvin, AJ | 1 |
| Smith, DC | 1 |
| Williams, RD | 1 |
| See, WA | 1 |
| Motzer, RJ | 1 |
| Nanus, DM | 1 |
| O'Moore, P | 1 |
| Scher, HI | 1 |
| Bajorin, DF | 1 |
| Reuter, V | 1 |
| Tong, WP | 1 |
| Iversen, J | 1 |
| Louison, C | 1 |
| Albino, AP | 1 |
| Wade, TP | 1 |
| Kasid, A | 1 |
| Stein, CA | 3 |
| LaRocca, RV | 2 |
| Sargent, ER | 1 |
| Gomella, LG | 1 |
| Myers, CE | 3 |
| Linehan, WM | 1 |
| Chang, SY | 1 |
| Yu, DS | 1 |
| Sherwood, ER | 1 |
| Kozlowski, JM | 1 |
| Lee, C | 1 |
| La Rocca, RV | 1 |
| Danesi, R | 1 |
| Cooper, MR | 1 |
| Uhrich, M | 1 |
| Corliss, J | 1 |
| Thomas, R | 1 |
| McAtee, N | 1 |
| Sovová, V | 1 |
| Vydra, J | 1 |
| Cerná, H | 1 |
| Sloncová, E | 1 |
| Damková, M | 1 |
| Jakoubková, J | 1 |
| Hlozánek, I | 1 |
3 trials available for suramin and Cancer of Kidney
| Article | Year |
|---|---|
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 2008 |
Phase II trial of suramin in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Infusions, Intrave | 1999 |
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Growth Substances; Humans; Kidney Neoplasms; Male; Middl | 1992 |
10 other studies available for suramin and Cancer of Kidney
| Article | Year |
|---|---|
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Topics: Animals; Carcinoma, Renal Cell; Cell Division; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Ne | 1995 |
Comparative Gompertzian analysis of alterations of tumor growth patterns.
Topics: Animals; Carcinoma, Renal Cell; Cell Division; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; | 1994 |
The effects of coumarin and suramin on the growth of malignant renal and prostatic cell lines.
Topics: Carcinoma, Renal Cell; Cell Division; Coumarins; Humans; Kidney Neoplasms; Male; Prostatic Neoplasms | 1994 |
Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo.
Topics: Animals; Antibodies; Antineoplastic Agents; Cell Division; Cell Line; DNA, Neoplasm; Dose-Response R | 1996 |
Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture.
Topics: Carcinoma, Renal Cell; Cell Division; Dose-Response Relationship, Drug; Humans; Kidney Neoplasms; Su | 1992 |
Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction.
Topics: Animals; Carcinoma, Renal Cell; Cell Division; Chemical and Drug Induced Liver Injury; Combined Moda | 1992 |
A pilot study of suramin in the treatment of metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; | 1991 |
Heparin analogues: a new family of anticancer drugs.
Topics: Antineoplastic Agents; Humans; Kidney Neoplasms; Male; Prostatic Neoplasms; Suramin | 1989 |
Suramin: an anticancer drug with a unique mechanism of action.
Topics: Adenocarcinoma; Adrenal Cortex Neoplasms; Adult; Antineoplastic Agents; Carcinoma; Female; Humans; K | 1989 |
Analysis of epidermal growth factor and epidermal growth factor receptor expression in human renal carcinoma cell cultures.
Topics: Carcinoma, Renal Cell; Cell Division; Cell Line; Epidermal Growth Factor; ErbB Receptors; Humans; Ki | 1988 |